These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 19530741)

  • 21. Thiazolidinediones: do harms outweigh benefits?
    Lipscombe LL
    CMAJ; 2009 Jan; 180(1):16-7. PubMed ID: 19073650
    [No Abstract]   [Full Text] [Related]  

  • 22. [Daily practice using the guidelines for prevention and treatment of osteoporosis. Anti-diabetic agents and fracture risk].
    Okazaki R
    Clin Calcium; 2008 Aug; 18(8):1154-61. PubMed ID: 18677054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The current role of thiazolidinediones in diabetes management.
    Rizos CV; Kei A; Elisaf MS
    Arch Toxicol; 2016 Aug; 90(8):1861-81. PubMed ID: 27165418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of thiazolidinediones on bone loss and fracture.
    Murphy CE; Rodgers PT
    Ann Pharmacother; 2007 Dec; 41(12):2014-8. PubMed ID: 17940125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial.
    Gruntmanis U; Fordan S; Ghayee HK; Abdullah SM; See R; Ayers CR; McGuire DK
    Calcif Tissue Int; 2010 May; 86(5):343-9. PubMed ID: 20354684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of thiazolidinediones and fracture risk.
    Meier C; Kraenzlin ME; Bodmer M; Jick SS; Jick H; Meier CR
    Arch Intern Med; 2008 Apr; 168(8):820-5. PubMed ID: 18443256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thiazolidinedione safety.
    Kung J; Henry RR
    Expert Opin Drug Saf; 2012 Jul; 11(4):565-79. PubMed ID: 22616948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Type 2 diabetes, thiazolidinediones, and cardiovascular risk.
    Taylor C; Hobbs FD
    Br J Gen Pract; 2009 Jul; 59(564):520-4. PubMed ID: 19567003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus.
    Habib ZA; Havstad SL; Wells K; Divine G; Pladevall M; Williams LK
    J Clin Endocrinol Metab; 2010 Feb; 95(2):592-600. PubMed ID: 20061432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thiazolidinedione use and the risk of fractures.
    Reblin T
    CMAJ; 2009 Apr; 180(8):841. PubMed ID: 19364797
    [No Abstract]   [Full Text] [Related]  

  • 31. Insulin sensitization by a novel partial peroxisome proliferator-activated receptor γ agonist with protein tyrosine phosphatase 1B inhibitory activity in experimental osteoporotic rats.
    Kubo M; Fukui M; Ito Y; Kitao T; Shirahase H; Hinoi E; Yoneda Y
    J Pharmacol Sci; 2014; 124(2):276-85. PubMed ID: 24553405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes.
    Aubert RE; Herrera V; Chen W; Haffner SM; Pendergrass M
    Diabetes Obes Metab; 2010 Aug; 12(8):716-21. PubMed ID: 20590749
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men.
    Yaturu S; Bryant B; Jain SK
    Diabetes Care; 2007 Jun; 30(6):1574-6. PubMed ID: 17363747
    [No Abstract]   [Full Text] [Related]  

  • 34. Combined thiazolidinedione-insulin therapy: should we be concerned about safety?
    Scheen AJ
    Drug Saf; 2004; 27(12):841-56. PubMed ID: 15366973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recommendations on the effect of antidiabetic drugs in bone.
    Rozas-Moreno P; Reyes-García R; Jódar-Gimeno E; Varsavsky M; Luque-Fernández I; Cortés-Berdonces M; Muñoz-Torres M;
    Endocrinol Diabetes Nutr; 2017 Mar; 64 Suppl 1():1-6. PubMed ID: 28440761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk.
    Derosa G; Maffioli P
    Curr Mol Pharmacol; 2012 Jun; 5(2):272-81. PubMed ID: 22122457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glitazone use associated with reduced risk of Parkinson's disease.
    Brakedal B; Flønes I; Reiter SF; Torkildsen Ø; Dölle C; Assmus J; Haugarvoll K; Tzoulis C
    Mov Disord; 2017 Nov; 32(11):1594-1599. PubMed ID: 28861893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone.
    Simó R; Rodriguez A; Caveda E
    Curr Drug Saf; 2010 Jul; 5(3):234-44. PubMed ID: 20210732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of antidiabetic treatment on bone.
    Jackuliak P; Kužma M; Payer J
    Physiol Res; 2019 Nov; 68(Suppl 2):S107-S120. PubMed ID: 31842574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.